Minerva Neurosciences
NERV
68 hedge funds and large institutions have $63.2M invested in Minerva Neurosciences in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 26 reducing their positions, and 19 closing their positions.
171% more call options, than puts
Call options by funds: $964K | Put options by funds: $356K
1.22% less ownership
Funds ownership: 9.19% → 7.97% (-1.2%)
6% less funds holding
Funds holding: 72 → 68 (-4)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
32% less capital invested
Capital invested by funds: $92.9M → $63.2M (-$29.7M)
35% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.94M |
| 2 |
Renaissance Technologies
New York
|
+$1.51M |
| 3 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
+$692K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$669K |
| 5 |
D.E. Shaw & Co
New York
|
+$604K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.18M |
| 2 |
Goldman Sachs
New York
|
-$2.31M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$1.69M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.65M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.24M |
NERV Hedge Fund Activity: Q2 2021 in Review
68 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q2 2021, worth a combined $63.2M — down 32% from $92.9M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of NERV and 15 opened new positions — a net loss of 4 holders — while 26 trimmed existing stakes and 17 added.
The largest buyer was Millennium Management, adding an estimated $1.94M. The largest seller was BlackRock, cutting an estimated $5.18M.
- 68 institutional investors held Minerva Neurosciences (NERV) as of Q2 2021, down from 72 in Q1 2021.
- Funds reported $63.2M of Minerva Neurosciences stock for Q2 2021, down 32% quarter-over-quarter.
- 15 funds opened new Minerva Neurosciences positions in Q2 2021 and 19 closed out, a net change of -4 holders.
- The largest Minerva Neurosciences buyer in Q2 2021 was Millennium Management, an estimated $1.94M added.
- The largest Minerva Neurosciences seller in Q2 2021 was BlackRock, an estimated $5.18M sold.
Based on aggregated 13F filings for Q2 2021.